Abstract:Abstract Introduction TEV is the second highest cause of death in malignancy with 20% incidence. Platelets is a leading mediator of thrombosis as well as of tumor development. Indeed, thrombocytosis is a predictive biomarker of thrombosis risk and contributes to CAT burden. However, the management of thrombocytopenia in patients with CAT is well investigated, whereas evidence is poor on the management of patients with concomitant occurrence of thrombocytosis and CAT. Case report A 67 y-o woman, in primary thromboprophylaxis with 100 mg/die aspirin for myeloproliferative syndrome (PC: 771 x103/μl), was treated with left mastectomy for infiltrating ductal carcinoma (G3 pT1cN1a Mx Ki67:25%) and adjuvant chemotherapy with anthracyclines and anastrozole. Due to bone metastases, zoledronic acid, fulvestrant and palbociclib were administrated. For liver metastases, she was treated with exemestane, paclitaxel and bevacizumab and for disease progression, started capecitabine and cyclophosphamide, still ongoing. She experienced left jugular vein thrombosis (Fig 1-2) treated with edoxaban 60 mg/die with an almost total DVT regression after 2 months. The multidisciplinary team (oncologist, cardiologist, hematologist) decided to interrupt aspirin, proceeding antithrombotic therapy with edoxaban full dose. Concomitant cytoreductive therapy with hydroxyurea was started concomitantly with edoxaban. PC was reduced (522 x103/μl). After 1-month follow-up duplex ultrasound still documented mild persistence of the DVT (Fig 3-4), the patient was compliant and the anticancer regimens (addressed to both the solid cancer and the hematologic disease) were still administrated without any adverse effects. Conclusions CAT is a frequent and major complication of malignancy, worsening mortality, morbidity and decision-making. Platelets play a central role in promoting the hypercoagulable melieu of cancer as well as the metastases growth. Notably, thrombocytosis occurrence further increases the thrombogenic burden in malignancy; nevertheless, its concomitant development together with CAT is understudied. In the reported case, a solid tumor, together with hematologic cancer and DVT, concurred to a difficult management of a patient admitted to our multidisciplinary team. The use of a DOAC, edoxaban, at full dose, without concomitant therapy with aspirin, was an effective, safe and manageable antithrombotic treatment option, allowing the continuation of anticancer agents with no interruptions or delays. The knowledge of tumor-specific pathways may help to personalize strategies for CAT prevention. Fig 1-2 Fig 3-4

[Thrombotic occlusion of the extracorporeal circulation during hepatic chemosaturation despite targeted anticoagulation : A case report]

Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer

Are Autologous Bone Marrow Stem Cell Transplantation and Transcatheter Arterial Embolization the Best Choices for Patients with Hepatocellular Carcinoma and Hepatic Dysfunction? Report of a Case

Systematic sequential therapy for <i>ex vivo</i> liver resection and autotransplantation: A case report and review of literature

[Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]

Surgical treatment for huge hepatic cavernous hemangioma closely attached to inf erior vena cava

Arterial Therapies of Non-Colorectal Liver Metastases

The removal of floating right heart thrombi and pulmonary embolus using AngioJet device and venoarterial extracorporeal membrane oxygenation: a case report

Endovascular Management of Thrombosed Cavoportal Anastomosis After Liver Transplantation Using Catheter Directed Thrombolysis and Stent Placement: A Case Report

Transcatheter Arterial Chemoembolization Experience for Advanced Hepatocellular Carcinoma with Right Atrial Tumor Thrombus

Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy

S4570 Rescue PAATO/CAATO for Recurrent Peristomal Variceal Bleeding Secondary to Hepatic Metastases Causing Portal Hypertension

Analysis of patient's X-ray exposure in hepatic chemosaturation procedures: a single center experience

Hepatic arterial infusion chemotherapy with implantable arterial access port for advanced-stage hepatocellular carcinoma: a case report

Resolving a sticky situation: A case report of mechanical thrombectomy of Histoacryl emboli in the right atrium and inferior vena cava

[A Case of Liver Metastasis of Colorectal Cancer Successfully Treated with Hepatic Arterial Infusion Chemotherapy after Systemic Chemotherapy Was Difficult to Administer]

Challenging anticoagulation therapy for multiple primary malignant tumors combined with thrombosis: A case report and review of literature

Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy

Conversion therapy of a giant hepatocellular carcinoma with portal vein thrombus and inferior vena cava thrombus: A case report and review of literature

Endovascular Interventions of Cancer-Associated Venous Thromboembolism with Symptomatic Iliocaval Venous Thrombosis: A Case Report

13 CANCER-ASSOCIATED THROMBOSIS AND THROMBOCYTOSIS: THE EDOXABAN SOLUTION.